PharmAust has kicked-off its highly-anticipated Phase I clinical trials for its flagship anti-cancer drug Monepantel in dogs using the first batch of 2000 tablets manufactured to its new and better-tasting formulation. The initial component of the trial is designed to validate the performance of the drug in different dietary settings that dogs may encounter at home. First results are expected in the middle of March this year.
Related Data & Insights
-
-
Rank Company # 163rd I Synergy Group $1.14m 164th Zelira Therapeutics $1.02m 165th Singular Health $935.18k 166th PharmAust $841.71k 198 public companies - industrial WA ranked by total revenue
Data & Insights
Mentioned Organisations
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024